Analysts take a look at Circassia Pharmaceuticals Plc (LON:CIR) having this to say.

January 13, 2018 - By reb123z

 Analysts take a look at Circassia Pharmaceuticals Plc (LON:CIR) having this to say.
Investors sentiment decreased to 1 in Q3 2017. Its down 0.18, from 1.18 in 2017Q2. It dived, as 16 investors sold Circassia Pharmaceuticals Plc shares while 33 reduced holdings. 14 funds opened positions while 35 raised stakes. 16.23 million shares or 2.40% less from 16.63 million shares in 2017Q2 were reported.
Northern Tru holds 258,885 shares or 0% of its portfolio. Asset Mgmt Inc has 0.03% invested in Circassia Pharmaceuticals Plc (LON:CIR). Deutsche Retail Bank Ag accumulated 15,995 shares. California-based California State Teachers Retirement Systems has invested 0% in Circassia Pharmaceuticals Plc (LON:CIR). Dimensional Fund Advsr L P stated it has 942,699 shares. Parkside Finance National Bank And Trust has 16 shares for 0% of their portfolio. Invesco Limited invested 0% in Circassia Pharmaceuticals Plc (LON:CIR). Price T Rowe Associates Md has 0.01% invested in Circassia Pharmaceuticals Plc (LON:CIR). California Public Employees Retirement has 11,700 shares for 0% of their portfolio. Moreover, Pacific Alternative Asset Management Lc has 0.12% invested in Circassia Pharmaceuticals Plc (LON:CIR). Comerica National Bank accumulated 0.01% or 17,520 shares. Ls Invest Advsr Ltd Liability reported 599 shares. Pnc Fincl Grp Inc has 424 shares. Elk Creek Ltd Com accumulated 280,111 shares. Riverhead Cap Ltd Co accumulated 1,567 shares or 0% of the stock.

Circassia Pharmaceuticals Plc (LON:CIR) Ratings Coverage

Among 6 analysts covering Circassia Pharmaceuticals (LON:CIR), 3 have Buy rating, 0 Sell and 3 Hold. Therefore 50% are positive. Circassia Pharmaceuticals had 49 analyst reports since October 27, 2015 according to SRatingsIntel. The company was maintained on Wednesday, September 27 by Numis Securities. Numis Securities maintained Circassia Pharmaceuticals Plc (LON:CIR) rating on Thursday, April 7. Numis Securities has “Buy” rating and GBX 565 target. JP Morgan maintained Circassia Pharmaceuticals Plc (LON:CIR) on Tuesday, June 21 with “Overweight” rating. The firm earned “Hold” rating on Tuesday, April 25 by Cantor Fitzgerald. The stock has “Neutral” rating by JP Morgan on Monday, March 20. The firm has “Buy” rating by Peel Hunt given on Tuesday, April 19. The stock has “Add” rating by Peel Hunt on Friday, February 24. The stock has “Buy” rating by Numis Securities on Friday, March 11. The stock has “Overweight” rating by JP Morgan on Wednesday, September 28. The stock of Circassia Pharmaceuticals Plc (LON:CIR) has “Buy” rating given on Friday, May 26 by Numis Securities. Below is a list of Circassia Pharmaceuticals Plc (LON:CIR) latest ratings and price target changes.

04/01/2018 Broker: Peel Hunt Rating: Hold Old Target: GBX 130.00 New Target: GBX 130.00 Maintain
04/12/2017 Broker: Numis Securities Rating: Buy Old Target: GBX 180.00 New Target: GBX 180.00 Maintain
31/10/2017 Broker: Peel Hunt Rating: Hold Old Target: GBX 130.00 New Target: GBX 130.00 Maintain
28/09/2017 Broker: JP Morgan Rating: Neutral Old Target: GBX 120.00 New Target: GBX 110.00 Maintain
27/09/2017 Broker: Peel Hunt Rating: Hold Old Target: GBX 130.00 New Target: GBX 130.00 Maintain
27/09/2017 Broker: Numis Securities Rating: Buy Old Target: GBX 180.00 New Target: GBX 180.00 Maintain
08/09/2017 Broker: JP Morgan Rating: Neutral Maintain
07/09/2017 Broker: Numis Securities Rating: Buy New Target: GBX 180.00 Maintain

The stock decreased 0.42% or GBX 0.4 during the last trading session, reaching GBX 94.6. About 69,504 shares traded. Circassia Pharmaceuticals Plc (LON:CIR) has 0.00% since January 13, 2017 and is . It has underperformed by 16.70% the S&P500.

Circassia Pharmaceuticals plc, a specialty biopharmaceutical company, focuses on the development and commercialization of products for the treatment of asthma and chronic obstructive pulmonary disease . The company has market cap of 315.46 million GBP. It markets novel NIOX asthma management products directly to specialists in the United States, the United Kingdom, and Germany, as well as through a network of partners internationally. It currently has negative earnings. The companyÂ’s asthma products comprise Fliveo that targets substitution of Flixotide, which has approved in the United Kingdom, as well as developing Seriveo that targets direct substitution of Seretide.

More news for Circassia Pharmaceuticals Plc (LON:CIR) were recently published by: Ft.com, which released: “Circassia halts allergy programme after failed trials” on April 18, 2017. Ft.com‘s article titled: “Circassia shares drop after cat allergy drug fails in trial” and published on June 20, 2016 is yet another important article.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.